Qualigen Therapeutics, Inc. Announces Public Offering
CARLSBAD, Calif. — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) has announced the details of its public offering, pricing 14,724,058 shares of common stock at $0.13 per share. In addition, the company is offering pre-funded warrants that allow holders to purchase up to 11,972,754 shares at a price of $0.129 each, with an exercise price of $0.001 per share. These warrants can be exercised immediately upon issuance.
Reasons Behind the Offering
The gross proceeds from this offering are projected to be around $3.46 million before accounting for expenses related to the placement agent and other costs. Qualigen intends to allocate these funds to several important areas, including paying off a Senior Note issued previously and advancing its clinical and preclinical research efforts. Additionally, the financing will support general working capital and may facilitate the expansion of partnerships under the Co-Development Agreement with Marizyme, Inc. The company is also considering potential acquisition opportunities.
Company's Strategic Actions
Univest Securities, LLC has been selected as the exclusive placement agent for this offering. The public offering is contingent upon customary closing conditions, and it is expected that the closing will occur in the near future.
Registration and Compliance Information
This offering of securities is being conducted in accordance with a registration statement on Form S-1, which was filed with the SEC and has recently become effective. This process ensures that the company adheres to the necessary legal frameworks and complies with relevant regulations for such offerings.
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics is dedicated to developing innovative therapies that significantly impact the healthcare industry. Their focus on advancing unique therapeutic solutions distinguishes them in the biotech field. The company aims for growth through both organic means and strategic partnerships and collaborations that further their mission.
Frequently Asked Questions
What is the purpose of Qualigen's recent public offering?
The recent public offering is intended to raise funds for various corporate purposes, including settling debts and advancing clinical trials.
How many shares are being offered in the public offering?
The offering consists of 14,724,058 shares of common stock.
Who acted as the placement agent for the offering?
Univest Securities, LLC served as the exclusive placement agent.
What are pre-funded warrants?
Pre-funded warrants allow holders to purchase shares at a predetermined price and can be exercised immediately.
How does this offering affect Qualigen’s future plans?
The proceeds from the offering will help Qualigen implement its strategic initiatives and may enable the expansion of its partnerships and research capabilities.
